Summit Therapeutics Inc SMMT 深 滬
已收盤 02-06 16:00:00 美东时间
14.99
+1.140
+8.23%
華盛通- 最 高15.11
- 今 開14.12
- 成交量 270.39万股
- 最 低 14.04
- 昨 收 13.85
- 總市值 115.60亿
- 52周最高 36.91
- 市盈率 靜 --
- 換手率 0.35%
- 52周最低 13.83
- 委 比 -48.07%
- 總股本 7.71亿
- 歷史最高 36.91
- 量 比 0.75
- 振 幅 7.73%
- 歷史最低 0.66
- 每 手 1
- 風險率 3.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
Citizens Reiterates Market Outperform on Summit Therapeutics, Maintains $40 Price Target
Citizens analyst Reni J. Benjamin reiterates Summit Therapeutics (NASDAQ:SMMT) with a Market Outperform and maintains $40 price target.
01-30 22:25
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway
The FDA accepted Summit Therapeutics' application for its lung cancer drug ivonescimab, setting a November 2026 decision date after positive Phase 3 trial results.
01-30 01:28
BUZZ-U.S. STOCKS ON THE MOVE-Lockheed Martin, ManpowerGroup, Parker-Hannifin,
BUZZ-U.S. STOCKS ON THE MOVE-Lockheed Martin, ManpowerGroup, Parker-Hannifin, Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street looked set for a choppy open on Thursday as
01-29 23:48
BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin
BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street looked set for a choppy open on Thursday as investors wad
01-29 22:18
FDA Accepts Biologics License Application for Summit Therapeutics' Ivonescimab in EGFR-Mutated NSCLC
FDA Accepts Biologics License Application for Summit Therapeutics' Ivonescimab in EGFR-Mutated NSCLC Summit Therapeutics Inc. announced that the U.S. Food & Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) for ivonescimab in combination with chemotherapy for
01-29 20:30
美股夜盘 | Classover Holdings, Inc. Class B涨15.51%，PMGC Holdings Inc.涨4.14%
Classover Holdings, Inc. Class B涨15.51%；PMGC Holdings Inc.涨4.14%；Moderna涨4.02%
01-22 11:02
